NU 641 Advanced Pharmacology - QUIZ 1:
PRINCIPLES OF PHARMACODYNAMICS,
PHARMACOKINETICS, & PRESCRIBING -
Advanced Practice Prescriber Foundation
Exam
DOMAIN I: PHARMACODYNAMICS (Questions 1-9)
1. A 56-year-old patient with hypertension is currently well-controlled on metoprolol
succinate 50 mg daily. Due to a supply chain issue, the pharmacy substitutes
metoprolol tartrate 50 mg daily. One week later, the patient returns with BP 158/94 and
reports feeling "heart palpitations." Which pharmacodynamic principle BEST explains
this clinical failure?
A) Metoprolol tartrate is a partial agonist at beta-1 receptors
B) Metoprolol succinate and tartrate have different half-lives, leading to loss of 24-hour
beta-blockade with once-daily tartrate dosing
C) Metoprolol tartrate has lower intrinsic activity at beta-1 receptors
D) The patient developed tolerance to beta-blockade during the transition
[CORRECT ANSWER: B]
,Domain: Domain I: Pharmacodynamics - Receptor Occupancy & Duration of Action
Concept Tested: Pharmacodynamic implications of formulation differences –
Metoprolol succinate is an extended-release formulation designed for once-daily dosing
with stable 24-hour beta-blockade. Metoprolol tartrate is immediate-release with a
half-life of 3-7 hours, requiring twice-daily dosing to maintain therapeutic effect.
Pathophysiologic/Pharmacologic Mechanism: Beta-1 receptor blockade must be
sustained to maintain antihypertensive effect. When an immediate-release formulation
is substituted for extended-release at the same dose and frequency, trough
concentrations fall below therapeutic threshold, allowing sympathetic breakthrough
(tachycardia, hypertension).
Clinical Application: APRNs must understand that formulation equivalence is not
bioequivalence. Immediate-release and extended-release products are not
interchangeable without dose and frequency adjustment.
Correct Answer Justification: B correctly identifies that the different pharmacokinetic
profiles (not pharmacodynamic properties) result in inadequate receptor occupancy
over 24 hours.
Why Other Choices Are Wrong:
● [A]: Incorrect. Both metoprolol formulations contain the same active drug.
Neither is a partial agonist; both are competitive antagonists.
● [C]: Incorrect. Intrinsic activity (efficacy) is zero for all beta-blockers as
antagonists. Both formulations have identical intrinsic activity.
● [D]: Incorrect. Tolerance to beta-blockade develops over weeks to months, not
one week, and is not formulation-specific.
Key APRN Takeaway: Extended-release and immediate-release formulations of the
same drug are not interchangeable without careful assessment of dosing interval and
patient response.
,2. A 72-year-old patient with atrial fibrillation is started on digoxin. After 5 days of daily
dosing, the serum digoxin level is 1.8 ng/mL (therapeutic range 0.8-2.0 ng/mL). The
patient's renal function is normal. Based on the pharmacokinetic principle of steady
state, approximately how many more days of daily dosing would be required for the
digoxin level to plateau at its final concentration if the dose remains unchanged?
A) 1-2 days
B) 3-5 days
C) 7-10 days
D) 14-21 days
[CORRECT ANSWER: B]
Domain: Domain I: Pharmacodynamics/Pharmacokinetics Interface - Steady State
Kinetics
Concept Tested: Steady state is achieved after approximately 4-5 half-lives. Digoxin's
half-life in patients with normal renal function is 36-48 hours. After 5 days of daily
dosing, the patient has achieved approximately 3 half-lives (~75% of steady state). Full
steady state (95%+) requires 4-5 half-lives.
Pathophysiologic/Pharmacologic Mechanism: With repeated fixed dosing, drug
accumulation follows an exponential curve. Each half-life adds 50% of the remaining
distance to steady state. After 4 half-lives, ~94% of steady state is achieved; after 5
half-lives, ~97%.
, Clinical Application: APRNs must understand that therapeutic drug levels drawn before
steady state may be misleading. A level that appears therapeutic at day 5 may rise into
the toxic range by day 10.
Correct Answer Justification: B correctly identifies that 3-5 additional days
(approximately 2 more half-lives) are needed to reach full steady state.
Why Other Choices Are Wrong:
● [A]: Incorrect. This underestimates the time to steady state. Digoxin's long
half-life requires more time.
● [C]: Incorrect. This overestimates. 7-10 days would be 5-7 half-lives, far beyond
steady state.
● [D]: Incorrect. This describes drugs with extremely long half-lives (e.g.,
amiodarone, hydroxychloroquine), not digoxin.
Key APRN Takeaway: Steady state = 4-5 half-lives. Know your drug half-lives to interpret
levels correctly and avoid premature dose adjustments.
3. A 62-year-old male with chronic pain is started on morphine sulfate. After 2 weeks,
the dose requires escalation to achieve the same analgesic effect. This phenomenon is
BEST explained by:
A) Metabolic tolerance due to CYP450 enzyme induction
B) Pharmacodynamic tolerance due to opioid receptor desensitization and
down-regulation
C) P-glycoprotein induction at the blood-brain barrier
D) First-pass metabolism saturation
[CORRECT ANSWER: B]
PRINCIPLES OF PHARMACODYNAMICS,
PHARMACOKINETICS, & PRESCRIBING -
Advanced Practice Prescriber Foundation
Exam
DOMAIN I: PHARMACODYNAMICS (Questions 1-9)
1. A 56-year-old patient with hypertension is currently well-controlled on metoprolol
succinate 50 mg daily. Due to a supply chain issue, the pharmacy substitutes
metoprolol tartrate 50 mg daily. One week later, the patient returns with BP 158/94 and
reports feeling "heart palpitations." Which pharmacodynamic principle BEST explains
this clinical failure?
A) Metoprolol tartrate is a partial agonist at beta-1 receptors
B) Metoprolol succinate and tartrate have different half-lives, leading to loss of 24-hour
beta-blockade with once-daily tartrate dosing
C) Metoprolol tartrate has lower intrinsic activity at beta-1 receptors
D) The patient developed tolerance to beta-blockade during the transition
[CORRECT ANSWER: B]
,Domain: Domain I: Pharmacodynamics - Receptor Occupancy & Duration of Action
Concept Tested: Pharmacodynamic implications of formulation differences –
Metoprolol succinate is an extended-release formulation designed for once-daily dosing
with stable 24-hour beta-blockade. Metoprolol tartrate is immediate-release with a
half-life of 3-7 hours, requiring twice-daily dosing to maintain therapeutic effect.
Pathophysiologic/Pharmacologic Mechanism: Beta-1 receptor blockade must be
sustained to maintain antihypertensive effect. When an immediate-release formulation
is substituted for extended-release at the same dose and frequency, trough
concentrations fall below therapeutic threshold, allowing sympathetic breakthrough
(tachycardia, hypertension).
Clinical Application: APRNs must understand that formulation equivalence is not
bioequivalence. Immediate-release and extended-release products are not
interchangeable without dose and frequency adjustment.
Correct Answer Justification: B correctly identifies that the different pharmacokinetic
profiles (not pharmacodynamic properties) result in inadequate receptor occupancy
over 24 hours.
Why Other Choices Are Wrong:
● [A]: Incorrect. Both metoprolol formulations contain the same active drug.
Neither is a partial agonist; both are competitive antagonists.
● [C]: Incorrect. Intrinsic activity (efficacy) is zero for all beta-blockers as
antagonists. Both formulations have identical intrinsic activity.
● [D]: Incorrect. Tolerance to beta-blockade develops over weeks to months, not
one week, and is not formulation-specific.
Key APRN Takeaway: Extended-release and immediate-release formulations of the
same drug are not interchangeable without careful assessment of dosing interval and
patient response.
,2. A 72-year-old patient with atrial fibrillation is started on digoxin. After 5 days of daily
dosing, the serum digoxin level is 1.8 ng/mL (therapeutic range 0.8-2.0 ng/mL). The
patient's renal function is normal. Based on the pharmacokinetic principle of steady
state, approximately how many more days of daily dosing would be required for the
digoxin level to plateau at its final concentration if the dose remains unchanged?
A) 1-2 days
B) 3-5 days
C) 7-10 days
D) 14-21 days
[CORRECT ANSWER: B]
Domain: Domain I: Pharmacodynamics/Pharmacokinetics Interface - Steady State
Kinetics
Concept Tested: Steady state is achieved after approximately 4-5 half-lives. Digoxin's
half-life in patients with normal renal function is 36-48 hours. After 5 days of daily
dosing, the patient has achieved approximately 3 half-lives (~75% of steady state). Full
steady state (95%+) requires 4-5 half-lives.
Pathophysiologic/Pharmacologic Mechanism: With repeated fixed dosing, drug
accumulation follows an exponential curve. Each half-life adds 50% of the remaining
distance to steady state. After 4 half-lives, ~94% of steady state is achieved; after 5
half-lives, ~97%.
, Clinical Application: APRNs must understand that therapeutic drug levels drawn before
steady state may be misleading. A level that appears therapeutic at day 5 may rise into
the toxic range by day 10.
Correct Answer Justification: B correctly identifies that 3-5 additional days
(approximately 2 more half-lives) are needed to reach full steady state.
Why Other Choices Are Wrong:
● [A]: Incorrect. This underestimates the time to steady state. Digoxin's long
half-life requires more time.
● [C]: Incorrect. This overestimates. 7-10 days would be 5-7 half-lives, far beyond
steady state.
● [D]: Incorrect. This describes drugs with extremely long half-lives (e.g.,
amiodarone, hydroxychloroquine), not digoxin.
Key APRN Takeaway: Steady state = 4-5 half-lives. Know your drug half-lives to interpret
levels correctly and avoid premature dose adjustments.
3. A 62-year-old male with chronic pain is started on morphine sulfate. After 2 weeks,
the dose requires escalation to achieve the same analgesic effect. This phenomenon is
BEST explained by:
A) Metabolic tolerance due to CYP450 enzyme induction
B) Pharmacodynamic tolerance due to opioid receptor desensitization and
down-regulation
C) P-glycoprotein induction at the blood-brain barrier
D) First-pass metabolism saturation
[CORRECT ANSWER: B]
